October 22, 2020 – 3D Medicines, Inc., a biopharmaceutical company focusing on the R&D and commercialization of  immuno-oncology drugs, announced the strategic collaboration agreement on new drug discovery with XtalPi, a leading AI drug development technology company. 3D Medicines and XtalPi will collaborate in all aspects of the R&D of immuno-oncology drugs, from drug discovery to clinical development and commercialization, pushing forward the R&D technology innovation and market expansion of immuno-oncology drugs together.

3D Medicines, Inc. is a biopharmaceutical company focused on the R&D and commercialization of immuno-oncology drugs. With a mission to help people with cancer live longer and better, 3D Medicines is devoted to the development of differentiated immuno-oncology drugs for cancer patients worldwide, helping them live with prolonged survival time and a better quality of life. Immunotherapy is now universally recognized as an effective treatment, which aims to control and treat tumors by regulating the body's immune system. In the product pipeline of 3D Medincines, Envafolimab (KN035), the  PD-L1 antibody drug given via subcutaneous injection, is about to reach commercialization stage, and multiple products reached late-stage clinical trials, with the R&D progress steadily moving forward.

XtalPi is among the most influential companies across the globe in AI drug development. With tightly interwoven quantum physics, artificial intelligence, and cloud computing algorithms, XtalPi pushes forward the novel infrastructure building for AI-driven digitalized drug R&D, accelerating the R&D of novel drugs while improving the efficiency. XtalPi’s ID4 platform has unique advantages in molecule generation, virtual screening, accurate activity prediction and other critical aspects of drug development, enabling the exploration of super-large chemical spaces, the generation of novel molecules with over a million molecular weight, comprehensive evaluation of druggability, activity, ADME/T and other properties, and the development of high-quality lead compounds.

On the basis of the technological advantages and strong resources of both parties, 3D Medicines and XtalPi will collaborate to apply AI drug discovery technologies to the R&D of differentiated immuno-oncology drugs, effectively accelerating the R&D process of novel drugs, cutting the cost of immuno-oncology drugs from the source and benefiting cancer patients. Besides, the two companies also hope to expand their R&D directions and improve creativity with the help of AI technology.

“New drug R&D is a complicated systematic project, and all the pharmaceutical companies face the obstacles of high cost, long cycles and low success rate. Luckily, the development of AI technology provides hope for solving these problems. We hope that the collaboration between 3D Medicines and XtalPi can open up a new path for the R&D of immuno-oncology drugs, cut the R&D cost while improving the efficiency and quality of drug R&D, thus benefiting cancer patients worldwide.”

-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines, Inc.

“Both 3D Medicines and XtalPi are leading companies and pioneers in their own fields in China’s innovative pharmaceutical industry with a strong sense of social responsibility. The strategic collaboration is not only a combination of advantages and win-win cooperation, but also another attempt to apply AI drug development methods in anti-tumor drugs. We look forward to the combination of XtalPi’s drug discovery technologies based on quantum physics, artificial intelligence, and high-performance cloud computing algorithms, and 3D Medicines’ expertise in professional clinical R&D for anti-tumor drugs, thus bringing about brand new thinking and achievements for accelerating the discovery and development of anti-tumor drugs.”

-- Jian Ma, Ph.D., co-founder and CEO of XtalPi

About 3D Medicines, Inc.

3D Medicines, Inc. is a clinical-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated  immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with innovative biological and small-molecule anti-cancer drugs, as well as a professional team capable of global development, registration and commercialization operation.

About XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi’s ID4 platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide in a joint effort with partners. Since its founding, XtalPi has established in-depth collaborations with dozens of large and medium-sized international pharmaceutical companies and scientific research institutions, providing services including drug discovery and solid-form research.